<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-854
Date of Submission: 2025-01-10

This report was submitted by a Patient from Phillips Inc Medical Center concerning patient ANON-PX-3476. The subject is a 27-year-old other with a significant medical history including anxiety, type 2 diabetes, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 7mg, initiated on 2024-10-19 for Hypertension with the course ongoing; Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 327mg, initiated on 2024-10-19 for Neuropathic pain with the course ongoing.

On approximately 2024-12-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed order and advised drive. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Number available teacher by. Direction much example. Live get especially send senior effect.</data>
report_id: ADR-2025-854
report_date: '2025-01-10'
patient_details:
  patient_id: ANON-PX-3476
  gender: Other
  relevant_history:
  - anxiety
  - type 2 diabetes
  - atrial fibrillation
  age_at_reaction: 27
suspected_drugs:
- drug_name: Lisinopril
  dosage: 7mg
  route_of_administration: Subcutaneous
  start_date: '2024-10-19'
  indication_for_use: Hypertension
  drug_class: ACE inhibitor
- drug_name: Gabapentin
  dosage: 327mg
  route_of_administration: Intravenous
  start_date: '2024-10-19'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2024-12-13'
  severity: Severe
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed order and advised drive.
- symptom_name: Headache
  onset_date: '2024-12-13'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Phillips Inc Medical Center
reporter_type: Patient
notes: Number available teacher by. Direction much example. Live get especially send
  senior effect.
